The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated ...

In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma. In part 1 of our interview with ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Glioblastoma is the most common and most aggressive primary brain tumor, with an average survival after diagnosis of less than two years, and against which current treatments remain ineffective. In ...

Balancing the immune system is a delicate act. If it’s too weak, infections and cancer can take hold; if it’s too strong, autoimmune diseases or transplant rejection can occur. Researchers have ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short ...

HIV infects immune cells and establishes long-lasting infections that can progress to acquired immunodeficiency syndrome (AIDS) if left untreated. With the advancement of antiviral therapy (ART), HIV ...